AKT1 and neoplasm: It has been documented that targeting AKT/mTOR signaling pathway may inhibit tumor growth and multiple inhibitors of this pathway have been developed and are being assessed in the laboratory and in clinical trials, including bevacizumab, gefitinib, and docetaxel [21, 22].